Isabella Visuri
Isabella Visuri Befattning: Doktorand Organisation: Institutionen för medicinska vetenskaperE-post: aXNhYmVsbGEudmlzdXJpO29ydS5zZQ==
Telefon: 019 302181
Rum: X2102
Om Isabella Visuri
Isabella arbetar som läkare vid Universitetssjukhuset Örebro och är registrerad doktorand vid Örebro Universitet sedan år 2017. Det övergripande syftet med avhandlingen är att öka kunskapen om effekt och komplikationer vid behandling med biologiska läkemedel hos patienter med inflammatorisk tarmsjukdom.
Publikationer
Artiklar i tidskrifter |
Doktorsavhandlingar, sammanläggningar |
Konferensbidrag |
Manuskript |
Artiklar i tidskrifter
- Thunberg, J. , Grännö, O. , Bergemalm, D. , Eriksson, C. , Visuri, I. , Eberhardson, M. & Halfvarson, J. (2024). Comparative study of a point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levels. Scandinavian Journal of Gastroenterology, 59 (2), 150-155. [BibTeX]
- Visuri, I. , Eriksson, C. , Karlqvist, S. , Lykiardopoulos, B. , Karlén, P. , Grip, O. , Söderman, C. , Almer, S. & et al. (2023). Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study. Therapeutic Advances in Gastroenterology, 16. [BibTeX]
- Holmgren, J. , Fröborg, A. , Visuri, I. , Halfvarson, J. , Hjortswang, H. , Karling, P. , Myrelid, P. , Olén, O. & et al. (2023). The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study. Inflammatory Bowel Diseases, 19 (3), 339-348. [BibTeX]
- Eriksson, C. , Visuri, I. , Vigren, L. , Nilsson, L. , Kärnell, A. , Hjortswang, H. , Bergemalm, D. , Almer, S. & et al. (2021). Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG. Scandinavian Journal of Gastroenterology, 56 (11), 1304-1311. [BibTeX]
- Visuri, I. , Eriksson, C. , Olén, O. , Cao, Y. , Mårdberg, E. , Grip, O. , Gustavsson, A. , Hjortswang, H. & et al. (2021). Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register. Alimentary Pharmacology and Therapeutics, 54 (7), 931-943. [BibTeX]
- Shrestha, S. , Olén, O. , Eriksson, C. , Everhov, Å. H. , Myrelid, P. , Visuri, I. , Ludvigsson, J. F. , Schoultz, I. & et al. (2020). The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register. Scandinavian Journal of Gastroenterology, 55 (4), 430-435. [BibTeX]
Doktorsavhandlingar, sammanläggningar
- Visuri, I. (2024). Biological treatment in inflammatory bowel disease: clinical and therapeutic aspects. (Doctoral dissertation). (Sammanläggning) Örebro: Örebro University. [BibTeX]
Konferensbidrag
- Visuri, I. , Eriksson, C. , Mårdberg, E. , Grip, O. , Gustavsson, A. , Hjortswang, H. , Karling, P. , Montgomery, S. & et al. (2019). Anti-TNF agent drug survival in patients with IBD: real-world comparisons of individual anti-TNF agents based on the Swedish National Quality Registry for IBD (SWIBREG). I: Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
- Eriksson, C. , Bergemalm, D. , Vigren, L. , Nilsson, L. , Visuri, I. , Hjortswang, H. , Udumyan, R. , Almer, S. & et al. (2018). Clinical effectiveness of golimumab: Interim analysis of the observational study of patients with ulcerative colitis on golimumab in the Swedish National Quality Registry for IBD-GO-SWIBREG. I: Journal of Crohn's & Colitis. Konferensbidrag vid 13th Congress of ECCO – European Crohn’s and Colitis Organisation, Vienna, Austria, February 14-17, 2018. (ss. S409-S410). Oxford University Press. [BibTeX]
Manuskript
- Visuri, I. , Dannenberg, K. , Salomon, B. , Ling Lundström, M. , Bergemalm, D. , Eriksson, C. , Lindqvist, C. M. , Keita, Å. V. & et al. Correlations of clinical characteristics and serum proteins with drug levels : A multicentre cohort study of patients with inflammatory bowel disease starting biologics. [BibTeX]